Nightstar Therapeutics plc [●] American Depositary Shares Representing [●] Ordinary Shares (Nominal Value £0.01 Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • September 15th, 2017 • Nightstar Therapeutics LTD • Biological products, (no disgnostic substances) • New York
DEPOSIT AGREEMENT by and among NIGHTSTAR THERAPEUTICS PLC And CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [date], 2017Deposit Agreement • September 15th, 2017 • Nightstar Therapeutics LTD • Biological products, (no disgnostic substances) • New York
DEPOSIT AGREEMENT, dated as of , 2017, by and among (i) NIGHTSTAR THERAPEUTICS PLC, a public limited company incorporated under the laws of England and Wales, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • September 15th, 2017 • Nightstar Therapeutics LTD • Biological products, (no disgnostic substances) • Massachusetts
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), dated and entered into as of the 12th day of September, 2017 (“Effective Date”), by and between Nightstar, Inc., a Delaware corporation and wholly owned subsidiary of Nightstar Therapeutics Limited, a company incorporated under the laws of England and Wales (hereinafter referred to together as the “Company”) and David Fellows (the “Employee”).
ContractAgreement • September 15th, 2017 • Nightstar Therapeutics LTD • Biological products, (no disgnostic substances)
[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
